- Home
- NPCE vs OLMA Comparison
NPCE vs OLMA Comparison
Compare NPCE & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- OLMA
- Stock Information
- Founded
- NPCE 1997
- OLMA 2006
- Country
- NPCE United States
- OLMA United States
- Employees
- NPCE N/A
- OLMA N/A
- Industry
- NPCE Medical Specialities
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- OLMA Health Care
- Exchange
- NPCE Nasdaq
- OLMA Nasdaq
- Market Cap
- NPCE 292.9M
- OLMA 378.9M
- IPO Year
- NPCE 2021
- OLMA 2020
- Fundamental
- Price
- NPCE $9.15
- OLMA $5.46
- Analyst Decision
- NPCE Strong Buy
- OLMA Strong Buy
- Analyst Count
- NPCE 6
- OLMA 5
- Target Price
- NPCE $16.67
- OLMA $24.00
- AVG Volume (30 Days)
- NPCE 205.3K
- OLMA 450.7K
- Earning Date
- NPCE 08-12-2025
- OLMA 08-11-2025
- Dividend Yield
- NPCE N/A
- OLMA N/A
- EPS Growth
- NPCE N/A
- OLMA N/A
- EPS
- NPCE N/A
- OLMA N/A
- Revenue
- NPCE $88,570,000.00
- OLMA N/A
- Revenue This Year
- NPCE $22.13
- OLMA N/A
- Revenue Next Year
- NPCE $6.07
- OLMA N/A
- P/E Ratio
- NPCE N/A
- OLMA N/A
- Revenue Growth
- NPCE 23.32
- OLMA N/A
- 52 Week Low
- NPCE $5.45
- OLMA $2.86
- 52 Week High
- NPCE $18.98
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- NPCE 51.74
- OLMA 54.42
- Support Level
- NPCE $8.61
- OLMA $5.54
- Resistance Level
- NPCE $8.99
- OLMA $5.85
- Average True Range (ATR)
- NPCE 0.53
- OLMA 0.30
- MACD
- NPCE 0.11
- OLMA -0.01
- Stochastic Oscillator
- NPCE 75.00
- OLMA 51.79
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.